Focus Sector: Autoimmune Research & Clinical Access

MISSION

The Flare audits unpublished, shelved, withdrawn, and terminated clinical trial data in the autoimmune and oncology sectors. We translate raw data into transparent briefings for patients, families, advocacy groups, and independent researchers.

This briefing audits the APRIL-SLE trial (NCT00624338), in which the higher-dose atacicept arm was terminated early after two fatal pulmonary infections while simultaneously showing flare-reduction signals that shaped every major lupus biologic approved since. We track 2026 CAR-T trial activity, identify the Type I interferon pathway as the current organizing principle of lupus drug development, and flag a pending FDA decision on atacicept that closes an unexpected loop in the compound's regulatory history.

As of April 2026, the FDA officially approved the subcutaneous (self-injectable) version of Saphnelo. We also dive into another actively recruiting trial, and more drugs on the way in the FDA pipeline.

Trial ID: NCT00624338 (APRIL-SLE)

Sponsor and Location: EMD Serono Inc. / Merck KGaA, multi-site, including University College London, UC San Francisco, and University of Birmingham

The Mechanism of Action: In lupus, the immune system produces autoantibodies that attack the body's own tissues. Two proteins, BLyS and APRIL, act as survival signals that keep those misfiring immune cells alive. Atacicept was designed to block both signals simultaneously, cutting off the fuel supply to the cells responsible for lupus flares.

The Metric Discrepancy: The higher-dose arm of APRIL-SLE was terminated early following two fatal pulmonary infections in treated patients. Investigators could not definitively determine whether the deaths were caused by the drug, by the severity of the patients' underlying lupus, or by the combination of atacicept with other immunosuppressive medications the patients were already taking. Because that question could not be answered with the available data, the sponsor stopped the higher-dose arm as a precaution.

The termination record contains a detail that rarely reaches patient-facing coverage: the higher-dose arm was simultaneously showing signs of working. Patients in that group had fewer serious lupus flares than the placebo group, and those whose antibody levels dropped the most had the fewest new disease events. The trial stopped not because the drug failed, but because two patients died and the cause could not be confirmed.

What this trial contributed to the field was a caution about how deep immune suppression can go before it becomes dangerous. Lupus patients are already living with a compromised immune system, often on multiple medications that suppress it further. Blocking both BLyS and APRIL at once may have left some patients without enough immune reserve to fight serious infection. That finding shaped the drugs that came after. Belimumab blocks only one of those two signals, and its safety record reflects the difference. Anifrolumab, approved in 2021, works further upstream by blocking the signaling pathway that triggers the immune system's misfiring in the first place.

A 2026 footnote: Atacicept did not exit the regulatory pipeline. Under Vera Therapeutics, a formal approval application was submitted to the FDA in late 2025 for IgA nephropathy (IgAN), a progressive autoimmune kidney disease. The FDA granted Priority Review with a target decision date of July 7, 2026. The supporting trial showed a 46% reduction in a key marker of kidney damage, and the safety profile was comparable to placebo, a materially different outcome than APRIL-SLE. The mechanism was not abandoned. It was redirected.

Study Name and ClinicalTrials.gov ID: NCT06839976 — CART19 for Adolescents and Young Adults with SLE, Children's Hospital of Philadelphia (Phase 1/2, actively recruiting).
Additional U.S. sites: RESOLUTION trial, Norton Cancer Institute, Louisville, KY; UCI Health, Irvine, CA.
International: NCT06947460, CD19-BCMA CAR-T for Refractory Lupus Nephritis, Beijing GoBroad Hospital.

Who This Trial Is Looking For: The CHOP study (NCT06839976) is enrolling adolescents and young adults with active lupus, including those with kidney involvement, who have tried at least two treatments without adequate relief. Verify current recruitment status at ClinicalTrials.gov:NCT06839976 before contacting any site.

The Mechanism of Action: Most lupus medications suppress the immune system broadly. CAR-T therapy takes a more targeted approach: doctors collect the patient's own immune cells, reprogram them in a laboratory to seek out and destroy the specific cells producing the autoantibodies driving lupus, then reinfuse them. The goal is to eliminate the problem cells and allow the immune system to rebuild from a cleaner baseline. Some trial designs use donor cells, and some target more than one cell type at once.

If you have been newly diagnosed, this research shows where the treatment pipeline is heading. Current approved drugs require ongoing treatment and do not produce remission in everyone. CAR-T is being studied as a one-time intervention aimed at sustained, drug-free remission.

If you have already tried multiple treatments without adequate control, current trials are specifically enrolling patients who have not responded to standard therapies. In the CASTLE trial, every lupus patient treated went into remission within six months and remained off all lupus medications for the entire follow-up period. A review of 145 patients across 16 studies, presented at ACR 2025, found the majority stopped all immunosuppressive medications after a single CAR-T infusion.

These are early-phase trials. Long-term durability data is limited, not every patient responds, and access barriers are real. What the data supports is that this approach is producing results in patients for whom other treatments did not work.

Study Name and ClinicalTrials.gov ID: NCT07438496 — GARDENIA, a Phase 3 study of nipocalimab in adults with moderate to severe SLE, sponsored by Johnson & Johnson. Actively enrolling.

Who This Trial Is Looking For: Adults with moderate to severe SLE that is currently active. The Phase 2b JASMINE trial that preceded this study required a confirmed SLE diagnosis of at least six months and measurable ongoing disease activity. GARDENIA is designed for a broad, diverse adult SLE population. Verify current enrollment criteria and site locations directly at ClinicalTrials.gov: NCT07438496.

The Mechanism of Action: Nipocalimab works differently from most lupus drugs. Rather than suppressing the immune system broadly or targeting specific immune cells, it blocks a protein called FcRn, which the body uses to recycle IgG antibodies back into circulation. In lupus, many of those IgG antibodies are the autoantibodies doing the damage. By blocking the recycling process, nipocalimab lowers the overall level of those harmful antibodies in the body. The result is a reduction in the autoantibodies driving lupus activity without broadly shutting down immune function.

Why It Matters

The JASMINE Phase 2b trial, which ran across 228 patients, met its primary endpoint: significantly more patients on nipocalimab reduced their overall lupus disease activity compared to placebo at 24 weeks. The trial also showed steroid-sparing potential, meaning patients may be able to reduce or eliminate corticosteroid use alongside treatment. This is clinically significant because long-term steroid use carries its own serious side effects including bone loss, blood sugar changes, and cardiovascular risk. No new safety signals were identified in JASMINE. The FcRn blocking mechanism is also being studied in lupus nephritis specifically, and nipocalimab holds FDA Fast Track designation for SLE as of March 2026, which is intended to accelerate the review process if an approval application is eventually filed.

The Type I Interferon Signature

In lupus, the immune system's internal alarm, normally triggered by viruses, gets stuck in the on position, driving chronic inflammation with no infection present. Between 60 and 80 percent of lupus patients show evidence of this in their blood, detectable through a test called the interferon gene signature. It is not visible on a standard lab panel; it requires specialized testing.

This pathway is now the primary target for the newest generation of lupus drugs. Anifrolumab, FDA-approved in 2021, was the first designed to block it directly. Several additional drugs targeting the same mechanism are in early-phase trials, including litifilimab, deucravacitinib, and enpatoran. The interferon gene signature is also being used to identify which patients are most likely to respond before treatment begins.

The Neuro and Kidney Files: When Lupus Attacks the Brain and the Kidneys

Neuropsychiatric lupus can produce cognitive changes, mood disruption, and neuropathy even when blood markers appear stable. Lupus nephritis affects up to half of all SLE patients and is the primary driver of long-term organ damage in this population. Briefing #010 audits the diagnostic record on both and reviews what the current trial pipeline shows about where treatment is headed.

The following table reflects the current state of the SLE treatment pipeline as of May 2026, sourced from ClinicalTrials.gov, FDA announcements, and peer-reviewed trial records. It is intended as a reference map, not a recommendation. Always verify current trial status directly at ClinicalTrials.gov.

How to read this table: "Phase 3" means the final large-scale trial before an FDA approval application can be filed. "FDA review" means the application is already submitted. "Actively recruiting" means the trial may be accessible to you now — verify directly at ClinicalTrials.gov.

Disclaimer: The Flare is an independent investigative journalism outlet. We are not medical providers, clinical trial sites, or financial advisors. This information is for educational and journalistic purposes only and does not constitute medical advice.